Genmab A/S Q2 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Emily Field - Barclays - Analyst : Hi. Thanks for taking my question. I just wanted to ask -- I guess one kind of as a follow-up, just on Acasunlimab. When do you when do you expect to start enrolling patients in the Phase 3? Are you expecting that you used docetaxel as a control? Just how are you thinking about a potential change in standard of care with the potential put of the approval of Trop-2 ADCs? And then secondly, just -- now that you're going to have two wholly-owned projects that you're starting going into Phase 3, how should we think about Genmab R&D cost in '25 and '26 things?

Question: Xian Deng - UBS Investment Bank - Analyst : Hi, thank you for taking my questions. Two, please. The first one is on Acasunlimab. You mentioned now you are this is a wholly owned asset, but just wondering, would you still be open to focus on when you partner here or are you committed that this will be wholly owned going forward? And if you are open to new partners, what sort of things would you be looking for your ideal partner, please? So that's the first question. And the second one is, Acasunlimab data update for word long. Just wondering maybe if I'll talkies or what sort of things can we actually expect where we have a bigger patient size for the every six week off-peak? Thank you.

Question: Jonathan Chang - Leerink Partners - Analyst : Hi, guys. Thanks for taking my questions. First question, what are your latest thoughts on the next development steps I've been asked in ovarian cancer and when could we learn the details of the Phase 3 second-line plus platinum-resistant ovarian cancer study expected to start before the end of the year? And then as a follow-up to that, what is your confidence level in the ability of been asked to address patients across the biomarker spectrum in ovarian and how important is that to your strategy? Thank you.

Question: Asthika Goonewardene - Truist Securities - Analyst : Hi, guys. Thanks for taking my question and congrats on the progress and the impressive outlook that we could answer part of it for the second half this year and future. Wanted to go back to 1046 and also GEN1042. Tahi, you mentioned you were clear on what to expect and what not to expect that were lung. I'm curious if there are other conferences later in the year where you could provide an update for 1046, just given how exciting that the ASTRO data world, and we want to see more follow-up. And related to that in previous calls, I think we've kind of got the feeling that there might be something on 1042, perhaps in head and neck later on this year. Just wanted to check back on that and see that still possibility or what kind of uptake we can expect in the future as well. Thanks.

Question: Peter Verdult - Citigroup Inc. - Analyst : Yes, thank you. Peter Verdult, Citi. Three question, please. Again speaking to the Pfizer Oncology team, they've got for head-and-neck cancer assets that they could go into Phase 3. Well, they're saying they're all well. So I just wanted to confirm and apologies if I've missed this, but is the head and neck Phase 3 program for TIDVAK confirmed or we do we await confirmation of that. And then Tahi or Jan, I'm sorry to test your patience, but What is the latest on HexaBody time lines in terms of data release and J&J decision? Or is it unchanged since the last update, again, apologies for testing your patience? Thank you.

Question: Peter Verdult - Citigroup Inc. - Analyst : Can just to be clear, sorry, to be clear. I mean, is our Phase I Phase 3 program confirmed, are you awaiting that data first?

Question: Peter Verdult - Citigroup Inc. - Analyst : Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 08, 2024 / 4:00PM, GMAB.CO - Q2 2024 Genmab A/S Earnings Call

Question: Yaron Werber - TD Cowen - Analyst : Great. I also just want to make a quick follow up on Acasunlimab. So I just want to confirm. So it sounds like the Phase 3 is only been with us through the Q6 week on head to head against dose of Taxol. And can you I don't know if you can comment it would primarily be just PFS or is it going to be PFS and OS kind of co-primary? Thank you.

Question: Matthew Pfau - William Blair & Company - Analyst : I'm sorry about the baground noises in the question. You've had a nice launch of EPKINLY in lymphoma. So far to date in the DLBCL space. Just wondering how we should think about uptake in follicular lymphoma given already in an accurate or not, right, because we share a second term and mid term. Thank you.

Question: Michael Schmidt - Guggenheim Partners - Analyst : Hey, thanks for taking my questions. I had of a commercial question, a follow up on epcoritamab. I'm just thinking ahead, wondering how we should think about the launch trajectory perhaps in follicular lymphoma relative to the initial launch in DLBCL, given presumably there's a fair amount of commercial synergies with this sleep expansion and gem in DLBCL specifically, how much visibility do you have perhaps based on claims data and other sources on how the drug is used relative to other treatment options, beat other antibodies or CAR-T cell therapies? Thanks so much.

Question: Ranjan Sharma - Goldman Sachs - Analyst : Hi. Thanks for taking my question. Just one follow up on EPKINLY actually Antony Mancini that is you made a comment in the prepared remarks that the launch is exceeding your expectations. And so I'd just be interested in what's driving that. Is that better uptake than you were initially expecting? Or is it actually potentially a larger market in third-line DLBCL and then you than you were initially expecting? And then secondly, actually on EPKINLY, again, in the past, you've talked to potential for moving the need for hospitalization from the DLBCL label. Could you just provide an update on progress there and when it could actually be reflected in the label? Thank you.

Question: Yifeng Liu - HSBC Bank Plc - Analyst : Hi. Thanks for taking my question. I got one Acasunlimab. Just based on the Phase 2 data. So obviously, the for the six weeks dosing regimen. How do you think about incorporating those responders in your Phase 3 design? And secondly, on also on, acasunlimab, on the bounce-back gross up, of course, there is anything that being taking into account in your 2025? Or is everything so taken account already in 2024 guidance? And thirdly, maybe could you give an update on you have core DLBCL Phase 3 trial deal, DLBCL, one Phase 3 trial, the second line transplant ineligible and DLBCL? Thanks.

Question: Yifeng Liu - HSBC Bank Plc - Analyst : So just maybe I can make myself clear. Just because I think IND in the Phase 2 results and the overall survival benefit is pretty predominately driven by the responders. Just wonder how you taking that thinking into a Phase 3 design in terms of maybe opportunity to recruiting more potentially that patient can respond better. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 08, 2024 / 4:00PM, GMAB.CO - Q2 2024 Genmab A/S Earnings Call

Question: Yifeng Liu - HSBC Bank Plc - Analyst : Thank you. That's really helpful. Thank you very much.

Question: Mattias Haggblom - Handelsbanken capital Markets - Analyst : Please ask your question because so much of that 700, I cannot keep it to one. So BioNTech face the decision to opt out from Aker, certainly not on their earnings call as we are all going to have critical mass in non-small cell lung cancer. So judging from the market traction on the day, you Surround House investor, we're obviously disappointed by the chain. So where, in particular, do you think Genmab and BioNTech valued asset differently. I guess I'm trying to better understand, given what you described with Ask Us, unprecedented was data if you think there's something in particular with the asset data generated. So far profile with a molecule that you perhaps appreciated more than your partner did. Thanks so much.